442 related articles for article (PubMed ID: 25553994)
41. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia.
Nutman A; Glick R; Temkin E; Hoshen M; Edgar R; Braun T; Carmeli Y
Clin Microbiol Infect; 2014 Dec; 20(12):O1028-34. PubMed ID: 24930471
[TBL] [Abstract][Full Text] [Related]
42. Diabetic status and the relationship of blood glucose to mortality in adults with carbapenem-resistant Acinetobacter baumannii complex bacteremia.
Leung CH; Liu CP
J Microbiol Immunol Infect; 2019 Aug; 52(4):654-662. PubMed ID: 31446929
[TBL] [Abstract][Full Text] [Related]
43. Clinical outcomes of children with carbapenem-resistant Acinetobacter baumannii bacteremia.
Vandepitte WP; Berge J; Andersson R
J Med Assoc Thai; 2014 Nov; 97 Suppl 11():S129-39. PubMed ID: 25509707
[TBL] [Abstract][Full Text] [Related]
44. Risk Factors for Mortality in Children with
Choe YJ; Lee HJ; Choi EH
Microb Drug Resist; 2019 Oct; 25(8):1210-1218. PubMed ID: 31120349
[No Abstract] [Full Text] [Related]
45. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study.
Zilberberg MD; Kollef MH; Shorr AF
J Hosp Med; 2016 Jan; 11(1):21-6. PubMed ID: 26353076
[TBL] [Abstract][Full Text] [Related]
46. Comparison of pneumonia- and non-pneumonia-related Acinetobacter baumannii bacteremia: Impact on empiric therapy and antibiotic resistance.
Teng SO; Yen MY; Ou TY; Chen FL; Yu FL; Lee WS
J Microbiol Immunol Infect; 2015 Oct; 48(5):525-30. PubMed ID: 25103719
[TBL] [Abstract][Full Text] [Related]
47. Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia.
Chusri S; Chongsuvivatwong V; Silpapojakul K; Singkhamanan K; Hortiwakul T; Charernmak B; Doi Y
J Microbiol Immunol Infect; 2019 Oct; 52(5):796-806. PubMed ID: 31031096
[TBL] [Abstract][Full Text] [Related]
48. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
[TBL] [Abstract][Full Text] [Related]
49. Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case-control study.
Henig O; Weber G; Hoshen MB; Paul M; German L; Neuberger A; Gluzman I; Berlin A; Shapira C; Balicer RD
Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):2063-8. PubMed ID: 26205665
[TBL] [Abstract][Full Text] [Related]
50. Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients.
Lee HY; Chen CL; Wu SR; Huang CW; Chiu CH
Crit Care Med; 2014 May; 42(5):1081-8. PubMed ID: 24394630
[TBL] [Abstract][Full Text] [Related]
51. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
[TBL] [Abstract][Full Text] [Related]
52. Risk factors for 30-day mortality in patients with carbapenem-resistant Acinetobacter baumannii during an outbreak in an intensive care unit.
Prates CG; Martins AF; Superti SV; Lopes FS; Ramos F; Cantarelli VV; Zavascki AP
Epidemiol Infect; 2011 Mar; 139(3):411-8. PubMed ID: 20513254
[TBL] [Abstract][Full Text] [Related]
53. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.
Sheng WH; Wang JT; Li SY; Lin YC; Cheng A; Chen YC; Chang SC
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):380-6. PubMed ID: 21558048
[TBL] [Abstract][Full Text] [Related]
54. Risk factors and clinical outcome of sulbactam nonsusceptibility in monomicrobial Acinetobacter nosocomialis bacteremia.
Lai HH; Liou BH; Chang YY; Kuo SC; Lee YT; Chen TL; Fung CP
J Microbiol Immunol Infect; 2016 Jun; 49(3):371-7. PubMed ID: 25081987
[TBL] [Abstract][Full Text] [Related]
55. Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates.
Kopterides P; Koletsi PK; Michalopoulos A; Falagas ME
Int J Antimicrob Agents; 2007 Nov; 30(5):409-14. PubMed ID: 17851052
[TBL] [Abstract][Full Text] [Related]
56. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
[TBL] [Abstract][Full Text] [Related]
57. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
Dickstein Y; Lellouche J; Ben Dalak Amar M; Schwartz D; Nutman A; Daitch V; Yahav D; Leibovici L; Skiada A; Antoniadou A; Daikos GL; Andini R; Zampino R; Durante-Mangoni E; Mouton JW; Friberg LE; Dishon Benattar Y; Bitterman R; Neuberger A; Carmeli Y; Paul M;
Clin Infect Dis; 2019 Aug; 69(5):769-776. PubMed ID: 30462182
[TBL] [Abstract][Full Text] [Related]
58. Predictors of mortality in Acinetobacter baumannii bacteremia.
Chen HP; Chen TL; Lai CH; Fung CP; Wong WW; Yu KW; Liu CY
J Microbiol Immunol Infect; 2005 Apr; 38(2):127-36. PubMed ID: 15843858
[TBL] [Abstract][Full Text] [Related]
59. A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia.
Ng TM; Teng CB; Lye DC; Apisarnthanarak A
Infect Control Hosp Epidemiol; 2014 Jan; 35(1):49-55. PubMed ID: 24334798
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure.
Liou BH; Lee YT; Kuo SC; Liu PY; Fung CP
Antimicrob Agents Chemother; 2015; 59(6):3637-40. PubMed ID: 25824230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
